Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Five Prime Therapeutics, Inc.”

67 pharma patents match "Five Prime Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 67
Index total 30,257
Page 2 / 3

Quick answer

This filtered view shows 67 pharmaceutical patents matching "Five Prime Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

67 results for “Five Prime Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 10618967

    Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

    Five Prime Therapeutics, Inc. · Granted Apr 14, 2020 · Expires Apr 9, 2040

    granted

  2. US 10562970

    Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Five Prime Therapeutics, Inc. · Granted Feb 18, 2020 · Expires Feb 13, 2040

    granted

  3. US 10537611

    Methods of treating lung cancer

    Five Prime Therapeutics, Inc. · Granted Jan 21, 2020 · Expires Jan 16, 2040

    granted

  4. US 10273281

    CD80 extracellular domain polypeptides and their use in cancer treatment

    Five Prime Therapeutics, Inc. · Granted Apr 30, 2019 · Expires Apr 25, 2039

    granted

  5. US 10221244

    Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

    Five Prime Therapeutics, Inc. · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  6. US 10221243

    Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Five Prime Therapeutics, Inc. · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  7. US 10172937

    Method of treatment of malignant solid tumors with afucosylated anti-FGFR2IIIb antibodies

    Five Prime Therapeutics, Inc. · Granted Jan 8, 2019 · Expires Jan 3, 2039

    granted

  8. US 10040858

    Anti-CSF1R antibodies for treating PVNS

    Five Prime Therapeutics, Inc. · Granted Aug 7, 2018 · Expires Aug 2, 2038

    granted

  9. US 10016484

    Methods of treating lung cancer

    Five Prime Therapeutics, Inc. · Granted Jul 10, 2018 · Expires Jul 5, 2038

    granted

  10. US 9957327

    Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Five Prime Therapeutics, Inc. · Granted May 1, 2018 · Expires Apr 26, 2038

    granted

  11. US 9775881

    Methods of treating mesothelioma by administration of compounds comprising FGFR1 ECD

    Five Prime Therapeutics, Inc. · Granted Oct 3, 2017 · Expires Sep 28, 2037

    granted

  12. US 9765147

    Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer

    Five Prime Therapeutics, Inc. · Granted Sep 19, 2017 · Expires Sep 14, 2037

    granted

  13. US 9695243

    Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Five Prime Therapeutics, Inc. · Granted Jul 4, 2017 · Expires Jun 29, 2037

    granted

  14. US 9475871

    Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins

    Five Prime Therapeutics, Inc. · Granted Oct 25, 2016 · Expires Oct 20, 2036

    granted

  15. US 9200075

    Nucleic acids encoding antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Five Prime Therapeutics, Inc. · Granted Dec 1, 2015 · Expires Nov 26, 2035

    granted

  16. US 9192683

    Methods of treating disease with FGFR1 fusion proteins

    Five Prime Therapeutics, Inc. · Granted Nov 24, 2015 · Expires Nov 19, 2035

    granted

  17. US 9173957

    FGFR2 fusion proteins comprising C-terminal deletion mutants of FGFR2-IIIC

    Five Prime Therapeutics, Inc. · Granted Nov 3, 2015 · Expires Oct 29, 2035

    granted

  18. US 9175065

    FGFR extracellular domain acidic region muteins

    Five Prime Therapeutics, Inc. · Granted Nov 3, 2015 · Expires Oct 29, 2035

    granted

  19. US 9169313

    Method of treatment of cancers characterized by ligand-dependent activating mutations in FGFR2 with FGFR1 ECD proteins

    Five Prime Therapeutics, Inc. · Granted Oct 27, 2015 · Expires Oct 22, 2035

    granted

  20. US 8951972

    FGFR1 extracellular domain combination therapies for lung cancer

    Five Prime Therapeutics, Inc. · Granted Feb 10, 2015 · Expires Feb 5, 2035

    granted

  21. US 8920800

    Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins

    Five Prime Therapeutics, Inc. · Granted Dec 30, 2014 · Expires Dec 25, 2034

    granted

  22. US 8747845

    Methods of treatment by administering antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Five Prime Therapeutics, Inc. · Granted Jun 10, 2014 · Expires Jun 5, 2034

    granted

  23. US 8685931

    Hair growth methods using FGFR3 extracellular domains

    Five Prime Therapeutics, Inc. · Granted Apr 1, 2014 · Expires Mar 27, 2034

    granted

  24. US 8614183

    Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2

    Five Prime Therapeutics, Inc. · Granted Dec 24, 2013 · Expires Dec 19, 2033

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.